Biomarkers for Kawasaki Disease: Clinical Utility and the Challenges Ahead

• Published in: Frontiers in pediatrics Vol. 7; p. 242
• Main Authors: Chaudhary, Himanshi, Nameirakpam, Johnson, Kumrah, Rajni, Pandiarajan, Vignesh, Suri, Deepti, Rawat, Amit, Singh, Surjit
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 18.06.2019
• Subjects: biomarkers; childhood vasculitis; immunology; Kawasaki; Pediatrics; vasculitis; vasculitis; Kawasaki; childhood vasculitis; immunology; biomarkers
• ISSN: 2296-2360; 2296-2360
• DOI: 10.3389/fped.2019.00242

Kawasaki disease (KD) has replaced acute rheumatic fever as the most common cause of acquired heart disease in children in the developed world and is increasingly being recognized from several developing countries. It is a systemic vasculitis with a predilection for coronary arteries. The diagnosis is based on a constellation of clinical findings that appear in a temporal sequence. Quite understandably, this can become a problem in situations wherein the clinical features are not typical. In such situations, it can be very difficult, if not impossible, to arrive at a diagnosis. Several biomarkers have been recognized in children with acute KD but none of these has reasonably high sensitivity and specificity in predicting the course of the illness. A line up of inflammatory, proteomic, gene expression and micro-RNA based biomarkers has been studied in association with KD. The commonly used inflammatory markers e.g. erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and total leucocyte counts (TLC) lack specificity for KD. Proteomic studies are based on the identification of specific proteins in serum, plasma and urine by gel electrophoresis. A host of genetic studies have identified genes associated with KD and some of these genes can predict the course and coronary outcomes in the affected individuals. Most of these tests are in the early stages of their development and some of these can predict the course, propensity to develop coronary artery sequelae, intravenous immunoglobulin (IVIg) resistance and the severity of the illness in a patient. Development of clinical criteria based on these tests will improve our diagnostic acumen and aid in early identification and prevention of cardiovascular complications.